The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Open accessPublished version of a preprint
Abstract
BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. METHODS: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a standard enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modified (PF4-enhanced) platelet-activation test to detect platelet-activating antibodies under various reaction conditions. Included in this testing were samples from patients who had blood samples referred for investigation of vaccine-associated thrombotic events, with 28 testing positive on a screening PF4-heparin immunoassay. RESULTS: Of the 11 original patients, 9 were women, with a median age of 36 years (range, 22 to 49). Beginning 5 to 16 days after vaccination, the patients presented with one or more thrombotic events, with the exception of 1 patient, who presented with fatal intracranial hemorrhage. Of the patients with one or more thrombotic events, 9 had cerebral venous thrombosis, 3 had splanchnic-vein thrombosis, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died. Five patients had disseminated intravascular coagulation. None of the patients had received heparin before symptom onset. All 28 patients who tested positive for antibodies against PF4-heparin tested positive on the platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin, Fc receptor-blocking monoclonal antibody, and immune globulin (10 mg per milliliter). Additional studies with PF4 or PF4-heparin affinity purified antibodies in 2 patients confirmed PF4-dependent platelet activation. CONCLUSIONS: Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thrombocytopenia and immune thrombocytopenia (ITP) were also included due to their association with TTS and reports of ITP as an independent safety signal [7,19,20].”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-1932 and Ad26.COV2.S (Johnson & Johnson–Janssen) Covid-19 vaccines,33 both of which are adenoviral vector vaccines.”
From Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuker, A. C., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 755
Self-citationCLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
Greinacher, A. (2015) · PubMed · doi:10.1056/nejmcp1411910 · Cited by 612
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
Warkentin, T. E., & Kelton, J. G. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-7-200110020-00009 · Cited by 463
Self-citationAutoimmune heparin‐induced thrombocytopenia
Greinacher, A., Selleng, K., & Warkentin, T. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13813 · Cited by 414
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A. J., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 268
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Warkentin, T. E., Pai, M., & Linkins, L. (2017) · Blood · doi:10.1182/blood-2017-04-778993 · Cited by 210
Self-citationWarkentin, T. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1636645 · Cited by 180
Self-citationA Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
Warkentin, T. E., Makris, M., Jay, R. M., & Kelton, J. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.012 · Cited by 170
Self-citationJuhl, D., Eichler, P., Lübenow, N., Strobel, U., Wessel, A., & Greinacher, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00621.x · Cited by 170
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,001
Hielscher, F., Schmidt, T., Klemis, V., Wilhelm, A., Marx, S., Abu‐Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Sester, U., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105321 · Cited by 35
Burn, E., Li, X., Delmestri, A., Jones, N., Duarte‐Salles, T., Reyes, C., Martínez‐Hernández, E., Martí, E., Verhamme, K. M. C., Rijnbeek, P. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34668-w · Cited by 43
Thakur, K. T., Tamborska, A., Wood, G. K., McNeill, E. N., Roh, D. J., Akpan, I. J., Miller, E. C., Bautista, A. E., Claassen, J., Kim, C. Y., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117532 · Cited by 37
Kircheis, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910791 · Cited by 34
Favaloro, E. J., Pasalic, L., & Lippi, G. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1039 · Cited by 33
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 34
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Niesen, M. J. M., Pawlowski, C., O’Horo, J. C., Challener, D. W., Silvert, E., Donadio, G., Lenehan, P. J., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7038 · Cited by 33
Silk, S. E., Kalinga, W. F., Mtaka, I. M., Lilolime, N. S., Mpina, M., Milando, F. A., Ahmed, S., Diouf, A., Mkwepu, F., Simon, B., et al. (2023) · Med · doi:10.1016/j.medj.2023.07.003 · Cited by 34
Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1996 · Cited by 34
Lau, C. L., Mayfield, H. J., Sinclair, J. E., Brown, S. J., Waller, M., Enjeti, A. K., Baird, A., Short, K. R., Mengersen, K. L., & Litt, J. C. B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.079 · Cited by 33
COVID-19, Vaccines, and Thrombotic Events: A Narrative Review
Abrignani, M. G., Murrone, A., Luca, L. D., Roncon, L., Lenarda, A. D., Valente, S., Caldarola, P., Riccio, C., Oliva, F. G., Gulizia, M. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040948 · Cited by 37
Maiese, A., Baronti, A., Manetti, A. C., Paolo, M. D., Turillazzi, E., Frati, P., & Fineschi, V. (2022) · Vaccines · doi:10.3390/vaccines10020308 · Cited by 33
Jenkin, D., Ritchie, A. J., Aboagye, J., Fedosyuk, S., Thorley, L., Provstgaard-Morys, S., Sanders, H., Bellamy, D. G., Makinson, R., Xiang, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00126-4 · Cited by 33
Hviid, A., Hansen, J. V., Thiesson, E. M., & Wohlfahrt, J. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2452 · Cited by 35
Ruhe, J., Schnetzke, U., Kentouche, K., Prims, F., Baier, M., Herfurth, K., Schlosser, M., Busch, M., Hochhaus, A., & Wolf, G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04584-y · Cited by 32
Prothrombotic Phenotype in COVID-19: Focus on Platelets
Barale, C., Melchionda, E., Morotti, A., & Russo, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413638 · Cited by 35
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID ‐19 Vaccination
Scutelnic, A., Krzywicka, K., Mbroh, J., van de Munckhof, A. A. G. A., van Kammen, M. S., de Sousa, D. A., Lindgren, E., Jood, K., Günther, A., Hiltunen, S., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26431 · Cited by 32
Alam, W. (2021) · Science Progress · doi:10.1177/00368504211025927 · Cited by 32
The Spike of SARS-CoV-2: Uniqueness and Applications
Kumavath, R., Barh, D., Andrade, B. S., Imchen, M., Aburjaile, F. F., Ch, A., Rodrigues, D. L. N., Tiwari, S., Alzahrani, K. J., Goés‐Neto, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663912 · Cited by 34
COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy
Hagan, K., Forman, R., Mossialos, E. A., Ndebele, P., Hyder, A. A., & Nasir, K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1999811 · Cited by 32
Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
GREGORIO, C. D., Colarusso, L., Calcaterra, G., Bassareo, P. P., Ieni, A., Mazzeo, A. T., Ferrazzo, G., Noto, A., Koniari, I. C., Mehta, J. L., et al. (2022) · Vaccines · doi:10.3390/vaccines10020232 · Cited by 37
Effectiveness of COVID‑19 vaccines and their challenges (Review)
Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 32
Gender Differences in Response to COVID-19 Infection and Vaccination
Zaher, K. A., Basingab, F. S., Alrahimi, J., Basahel, K., & Aldahlawi, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061677 · Cited by 43
Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications
Zhou, M., Xiao, H., Yang, X., Cheng, T., Yuan, L., & Xia, N. (2025) · MedComm · doi:10.1002/mco2.70056 · Cited by 35
Hazlewood, G. S., Pardo, J. P., Barnabe, C. C. M., Schieir, O., Barber, C. E. H., Bernatsky, S., Colmegna, I., Hitchon, C. A., Loeb, M. B., Mertz, D., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.210288 · Cited by 31
Favaloro, E. J., Henry, B. M., & Lippi, G. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13582 · Cited by 31
Gerotziafas, G., Catalano, M., Theodorou, Y., Dreden, P. V., Maréchal, V., Spyropoulos, A. C., Carter, C., Jabeen, N., Harenberg, J., Elalamy, I., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1535-8807 · Cited by 30
Weber, D. J., Al‐Tawfiq, J. A., Babcock, H. M., Bryant, K. A., Drees, M. L., Elshaboury, R. H., Essick, K., Fakih, M. G., Henderson, D. K., Javaid, W., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.322 · Cited by 33
Restoring vision using optogenetics without being blind to the risks
Harris, A. R., & Gilbert, F. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05477-6 · Cited by 31
Chen, J., Wang, B., Caserto, J. S., Shariati, K., Cao, P., Pan, Y., Xu, Q., & Ma, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101714 · Cited by 30
Possibility of exosome‑based coronavirus disease 2019 vaccine (Review)
Yoo, K. H., Thapa, N., Kim, B. J., Lee, J., Jang, Y. N., Chwae, Y., & Kim, J. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12542 · Cited by 30
Clinical Cardiovascular Adverse Events Reported Post-COVID-19 Vaccination: Are They a Real Risk?
Hana, D., Patel, K. B., Roman, S., Gattas, B. S., & Sofka, S. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101077 · Cited by 31
Wang, X., Gkrouzman, E., ANDRADE, D. C. O. D., Andréoli, L., Barbhaiya, M., Belmont, M. H., Branch, D. W., de Jesús, G. R., Efthymiou, M., Garcés, R. R., et al. (2021) · Lupus · doi:10.1177/09612033211062523 · Cited by 31
Signaling COVID-19 Vaccine Adverse Events
Harpaz, R., DuMouchel, W., van Manen, R. P., Nip, A., Bright, S., Szarfman, A., Tonning, J. M., & Lerch, M. (2022) · Drug Safety · doi:10.1007/s40264-022-01186-z · Cited by 31
Vogel, E., Kocher, K., Priller, A., Cheng, C., Steininger, P. A., Liao, B., Körber, N., Willmann, A., Irrgang, P., Held, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104294 · Cited by 31
Devaux, C. A., & Camoin‐Jau, L. (2023) · Viruses · doi:10.3390/v15051045 · Cited by 34
Esba, L. C. A., & Jeraisy, M. A. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1940145 · Cited by 29
Guillain‐Barré syndrome following ChAdOx1 nCoV‐19 COVID‐19 vaccination: A case series
James, J., Jose, J., Gafoor, V., Smita, B., & Balaram, N. (2021) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12537 · Cited by 30
Varona, J. F., Isidro, M. G., Moeinvaziri, M., Ramos-López, M., & Fernández‐Domínguez, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.06.025 · Cited by 30
Maadarani, O. S., Bitar, Z. I., Elzoueiry, M. M., Mohammad, N., Abdelfatah, M., Zaalouk, T. M., Mohsen, M., & Elhabibi, M. (2021) · JRSM Open · doi:10.1177/20542704211025259 · Cited by 30
Panovska-Stavridis, I. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.048 · Cited by 30
Dutta, A., Ghosh, R., Bhattacharya, D., Bhat, S., Ray, A., Pandit, A., Das, S., & Dubey, S. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.06.021 · Cited by 30
Liu, T., Dai, J., Yang, Z., Yu, X., Xu, Y., Shi, X., Wei, D., Tang, Z., Xu, G., Xu, W., et al. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.07.033 · Cited by 30
Kashir, J., Ambia, A. R., Shafqat, A., Sajid, M. R., AlKattan, K. M., & Yaqinuddin, A. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5covr0621-320rr · Cited by 31
Thrombotic events and COVID-19 vaccines
Brazete, C. S., Aguiar, A., Furtado, I., & Duarte, R. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0298 · Cited by 32
Coronavirus Disease 2019: Clinics, Treatment, and Prevention
Burkert, F. R., Lanser, L., Bellmann‐Weiler, R., & Weiß, G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761887 · Cited by 30
Elberry, M. H., Ahmed, H., Hamdallah, A., Abdella, W. S., Sayed, A., Ghaith, H. S., & Negida, A. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02626-w · Cited by 30
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S
Huynh, A., Arnold, D. M., Michael, J. V., Clare, R., Smith, J. W., Daka, M., Ianosi-Irimie, M., McKenzie, S. E., Kelton, J. G., & Nazy, I. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007336 · Cited by 30
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13819-5 · Cited by 32
Favaloro, E. J., Clifford, J., Leitinger, E., Parker, M., Sung, P., Chunilal, S. D., Tran, H. A., Kershaw, G. W., Fu, S., Passam, F. H., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15881 · Cited by 30
Jin, L., Tang, R., Wu, S., Guo, X., Huang, H., Hou, L., Chen, X., Zhu, T., Gou, J.-B., Zhong, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2155251 · Cited by 30
Ortega‐Paz, L., Arévalos, V., Fernández-Rodríguez, D., Díaz, V. A. J., Bañeras, J., Campo, G. C., Rodríguez-Santamarta, M., Fernández, J. F. D., Scardino, C., Gómez-Álvarez, Z., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279333 · Cited by 30
Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis
Schönborn, L., Seck, S. N., Thiele, T., Kaderali, L., Hoffmann, T., Hlinka, A., Lindhoff‐Last, E., Völker, U., Selleng, K., Buoninfante, A., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.027 · Cited by 30
Self-citationImmune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19)
Paulsen, F., Schaefers, C., Länger, F. P., Frenzel, C., Wenzel, U. O., Hengel, F. E., Bokemeyer, C., & Seidel, C. A. (2021) · Blood · doi:10.1182/blood.2021012790 · Cited by 29
Cardiovascular Complications of COVID-19 Vaccines
Liu, R., Pan, J., Zhang, C., & Sun, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840929 · Cited by 28
Taieb, A., & Mounira, E. (2022) · Vaccines · doi:10.3390/vaccines10122004 · Cited by 27
Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine
Finsterer, J., & Korn, M. (2021) · Brain Hemorrhages · doi:10.1016/j.hest.2021.06.001 · Cited by 29
Terpos, E., Politou, M., Ntanasis‐Stathopoulos, I., Karalis, V. D., Merkouri, E., Fotiou, D., Gavriatopoulou, M., Malandrakis, P., Kastritis, E., Trougakos, I. P., et al. (2021) · Vaccines · doi:10.3390/vaccines9070712 · Cited by 28
Gessler, F. A., Schmitz, A. K., Dubinski, D., Bernstock, J. D., Lehmann, F., Won, S., Wittstock, M., Güresir, E., Hadjiathanasiou, A., Zimmermann, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132777 · Cited by 29
MacIntyre, C. R., Veness, B. G., Berger, D., Hamad, N., & Bari, N. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.013 · Cited by 30
A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems
Shah, S. M., Alsaab, H. O., Rawas‐Qalaji, M., & Uddin, M. N. (2021) · Vaccines · doi:10.3390/vaccines9101086 · Cited by 29
Updates in Cerebral Venous Thrombosis
Alimohammadi, A., Kim, D. J., & Field, T. S. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01622-z · Cited by 32
The Ethics of Selective Mandatory Vaccination for COVID-19
Williams, B. (2021) · Public Health Ethics · doi:10.1093/phe/phab028 · Cited by 30
Hertel, M., Schmidt‐Westhausen, A. M., Wendy, S., Heiland, M., Nahles, S., Preißner, R., & Preißner, S. (2022) · Vaccines · doi:10.3390/vaccines10030480 · Cited by 30
Giryes, S., Bragazzi, N. L., Bridgewood, C., Marco, G. D., & McGonagle, D. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00928-6 · Cited by 32
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
Bissola, A.-L., Daka, M., Arnold, D. M., Smith, J. W., Moore, J. C., Clare, R., Ivetic, N., Kelton, J. G., & Nazy, I. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007766 · Cited by 29
Guo, W., Deguise, J., Tian, Y., Huang, P. C.-E., Goru, R., Yang, Q., Peng, S., Zhang, L., Zhao, L., Xie, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870599 · Cited by 29
COVID-19 vaccine-associated cerebral venous thrombosis in GermanyPreprint
Schulz, J. B., Berlit, P., Diener, H., Gerloff, C. P., Greinacher, A., Klein, C., Petzold, G. C., Piccininni, M., Poli, S., Röhrig, R., et al. (2021) · medRxiv · doi:10.1101/2021.04.30.21256383 · Cited by 29
Self-citationGordon, S. F., Clothier, H. J., Morgan, H., Buttery, J. P., Phuong, L. K., Monagle, P., Chunilal, S., Wood, E. M., Tran, H., Szer, J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.030 · Cited by 28
Rovetta, A. (2021) · JMIR Infodemiology · doi:10.2196/29929 · Cited by 28
Yang, X. S., Chen, M., Cao, L., & Zhao, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2270194 · Cited by 28
Schönborn, L., Pavord, S. R., Chen, V. M. Y., Pai, M., Gwarzo, D. H., Buttery, J. P., Muñoz, F. M., Tran, H. A., Greinacher, A., & LAW, B. J. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.045 · Cited by 28
Self-citationThrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience
Bano, F., Badugama, B., & Chandra, D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243894 · Cited by 28
Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination
Chuang, T.-Y., Burda, K., Teklemariam, E., & Athar, K. (2021) · Cureus · doi:10.7759/cureus.16791 · Cited by 28
Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia
Zahid, H., & Alsayb, M. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18158185 · Cited by 27
Azzarone, B. G., Veneziani, I., Moretta, L., & Maggi, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728513 · Cited by 28
Jeon, M., Kim, J., Oh, C. E., & Lee, J. (2021) · Vaccines · doi:10.3390/vaccines9101096 · Cited by 28
Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination
Ancău, M., Liesche‐Starnecker, F., Niederschweiberer, J., Krieg, S. M., Zimmer, C., Lingg, C., Kumpfmüller, D., Ikenberg, B. D., Ploner, M., Hemmer, B., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.820049 · Cited by 28
Stegner, D., Göb, V., Krenzlin, V., Beck, S., Hemmen, K., Schuhmann, M. K., Schörg, B. F., Hackenbroch, C., May, F., Burkard, P., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00017-1 · Cited by 28
Self-citationHemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination
Hieber, M.-L., Sprute, R., Eichenauer, D. A., Hallek, M. J., & Jachimowicz, R. D. (2022) · Infection · doi:10.1007/s15010-022-01786-y · Cited by 28
Lee, C. S. M., Liang, H., CONNOR, D. E., Dey, A., Tohidi‐Esfahani, I., Campbell, H., Whittaker, S. P., Capraro, D., Favaloro, E. J., Donikian, D., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006698 · Cited by 28
Anti-PF4 antibodies associated with disease severity in COVID-19
Liu, Q., Miao, H., Li, S., Zhang, P., Gerber, G. F., Follmann, D. A., Ji, H., Zeger, S. L., Chertow, D. S., Quinn, T. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213361119 · Cited by 28
Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews
Juvet, L. K., Robertson, A. H., Laake, I., Mjaaland, S., & Trogstad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740048 · Cited by 28
Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts
Dyer, O. (2021) · BMJ · doi:10.1136/bmj.n883 · Cited by 28
Gras‐Champel, V., Liabeuf, S., Baud, M., Albucher, J., Benkebil, M., Boulay, C., Bron, A., Kaddissi, A. E., Gautier, S., Geeraerts, T., et al. (2021) · Therapies · doi:10.1016/j.therap.2021.05.007 · Cited by 28
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Recent Advances in Immunothrombosis and Thromboinflammation
Kaiser, R. W. J., Gold, C., & Stark, K. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2523-1821 · Cited by 31
Bhan, C., Bheesham, N., Shakuntulla, F., Sharma, M., Sun, C., & Weinstein, M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2772 · Cited by 27
Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More
Lippi, G., & Favaloro, E. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1736168 · Cited by 27
Nakazawa, E., Uchimura, T., Hirai, Y., Togashi, H., Oyama, Y., Inaba, A., Shiga, K., & Ito, S. (2021) · CEN Case Reports · doi:10.1007/s13730-021-00656-0 · Cited by 27
Case report: Pituitary apoplexy after COVID-19 vaccination
Piñar-Gutiérrez, A., Remón-Ruiz, P., & Soto-Moreno, A. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.09.028 · Cited by 27
Sriwastava, S., Shrestha, A. K., Khalid, S. H., Colantonio, M. A., Nwafor, D. C., & Srivastava, S. (2021) · Neurology International · doi:10.3390/neurolint13040061 · Cited by 27
Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination
Krzywicka, K., van de Munckhof, A. A. G. A., van Kammen, M. S., Heldner, M. R., Jood, K., Lindgren, E., Tatlisumak, T., Putaala, J., Hovinga, J. A. K., Middeldorp, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013148 · Cited by 28
First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report
Osmanodja, B., Schreiber, A., Schrezenmeier, E. V., & Seelow, E. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02616-3 · Cited by 27
Bikdeli, B., Jiménez, D., Rodríguez, P. D., Valle, F. G., Porras, J. A., Barba, R., Ay, C., Malý, R., Braester, A., Imbalzano, E., et al. (2022) · Viruses · doi:10.3390/v14020178 · Cited by 27
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Yamada, S., & Asakura, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063338 · Cited by 33
Selvadurai, M. V., Favaloro, E. J., & Chen, V. M. Y. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1761269 · Cited by 27
Root-Bernstein, R. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24033001 · Cited by 29
Voss, E. A., Shoaibi, A., Lai, L. Y. H., Blacketer, C., Alshammari, T. M., Makadia, R., Haynes, K., Sena, A. G., Rao, G., Sandijk, S. V., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101932 · Cited by 34
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study
Campello, E., Simion, C., Bulato, C., Radu, C. M., Gavasso, S., Sartorello, F., Saggiorato, G., Zerbinati, P., Fadin, M., Spiezia, L., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.016 · Cited by 26
Metadata
- Authors
- Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Greinacher, Andreas
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-03
- Volume
- 384
- Issue
- 22
- Pages
- 2092-2101
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8095372
- OpenAlex
- W3140226555
- Cited by
- 2,259
- References
- 27
- Citations by year
- 2026: 77 · 2025: 139 · 2024: 171 · 2023: 297 · 2022: 725 · 2021: 848
- FWCI
- 479.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (Projektnummer 374031971 – TRR 240)
- Topics
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- ChAdOx1 nCoV-19 vaccine, AstraZeneca COVID-19 vaccine, vaccine-associated thrombosis, platelet factor 4, PF4/heparin antibodies, platelet-activating antibodies, cerebral venous thrombosis, pulmonary embolism, splanchnic vein thrombosis, disseminated intravascular coagulation, heparin, Fc receptor blockade, gamma globulin
- MeSH terms
- COVID-19 Vaccines, ChAdOx1 nCoV-19, Adult, Autoantibodies, Autoimmune Diseases, Blood Chemical Analysis, Disseminated Intravascular Coagulation, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Platelet Factor 4, Thrombocytopenia, Thrombosis, Platelet Activation, Fatal Outcome, Intracranial Hemorrhages, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
